» Articles » PMID: 35710549

Establishment of Combined Diagnostic Models of Alzheimer's Disease in a Chinese Cohort: the Chongqing Ageing & Dementia Study (CADS)

Abstract

Cerebrospinal fluid (CSF) biomarkers are essential for the accurate diagnosis of Alzheimer's disease (AD), yet their measurement levels vary widely across centers and regions, leaving no uniform cutoff values to date. Diagnostic cutoff values of CSF biomarkers for AD are lacking for the Chinese population. As a member of the Alzheimer's Association Quality Control program for CSF biomarkers, we aimed to establish diagnostic models based on CSF biomarkers and risk factors for AD in a Chinese cohort. A total of 64 AD dementia patients and 105 age- and sex-matched cognitively normal (CN) controls from the Chongqing Ageing & Dementia Study cohort were included. CSF Aβ42, P-tau181, and T-tau levels were measured by ELISA. Combined biomarker models and integrative models with demographic characteristics were established by logistic regression. The cutoff values to distinguish AD from CN were 933 pg/mL for Aβ42, 48.7 pg/mL for P-tau181 and 313 pg/mL for T-tau. The AN model, including Aβ42 and T-tau, had a higher diagnostic accuracy of 89.9%. Integrating age and APOE ε4 status to AN model (the ANA'E model) increased the diagnostic accuracy to 90.5% and improved the model performance. This study established cutoff values of CSF biomarkers and optimal combined models for AD diagnosis in a Chinese cohort.

Citing Articles

Hippocampal Subfield Volume in Relation to Cerebrospinal Fluid Amyloid-ß in Early Alzheimer's Disease: Diagnostic Utility of 7T MRI.

Adeyemi O, Gowland P, Bowtell R, Mougin O, Hosseini A Eur J Neurol. 2025; 32(2):e70076.

PMID: 39921301 PMC: 11806197. DOI: 10.1111/ene.70076.


A New Strategy for Ultrasensitive Detection Based on Target microRNA-Triggered Rolling Circle Amplification in the Early Diagnosis of Alzheimer's Disease.

Zhao F, Zhang N, Zhang Y Int J Mol Sci. 2024; 25(17).

PMID: 39273436 PMC: 11394956. DOI: 10.3390/ijms25179490.


Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS).

Liu Z, Shi D, Cai Y, Li A, Lan G, Sun P Alzheimers Res Ther. 2024; 16(1):84.

PMID: 38627753 PMC: 11020808. DOI: 10.1186/s13195-024-01458-z.


Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging.

Liu Y Mol Biol Rep. 2024; 51(1):121.

PMID: 38227160 DOI: 10.1007/s11033-023-09162-1.


Case of Autosomal Dominant Alzheimer Disease With Negative Findings From PiB-PET Examination.

Sun H, Wang Y, Wang Y, Zeng F Neurol Genet. 2023; 10(1):e200119.

PMID: 38130827 PMC: 10732343. DOI: 10.1212/NXG.0000000000200119.

References
1.
Ashton N, Pascoal T, Karikari T, Benedet A, Lantero-Rodriguez J, Brinkmalm G . Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021; 141(5):709-724. PMC: 8043944. DOI: 10.1007/s00401-021-02275-6. View

2.
Blennow K, Hampel H, Weiner M, Zetterberg H . Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010; 6(3):131-44. DOI: 10.1038/nrneurol.2010.4. View

3.
Van der Mussele S, Fransen E, Struyfs H, Luyckx J, Marien P, Saerens J . Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study. J Alzheimers Dis. 2014; 42(4):1239-50. DOI: 10.3233/JAD-140405. View

4.
Molinuevo J, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A . The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimers Dement. 2014; 10(6):808-17. DOI: 10.1016/j.jalz.2014.03.003. View

5.
Tijms B, Willemse E, Zwan M, Mulder S, Visser P, van Berckel B . Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results. Clin Chem. 2017; 64(3):576-585. DOI: 10.1373/clinchem.2017.281055. View